Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

HER2 and HER3-Directed Dendritic Cell Vaccine for the Treatment of Early Stage Triple Negative or Hormone Receptor Low Breast Cancer, The DecipHER Trial

Trial Status: active

This phase I clinical trial evaluates the best dose, safety, and effectiveness of a HER2 and HER3-directed dendritic cell vaccine prior to chemotherapy and surgery for the treatment of triple-negative or hormone receptor low breast cancer. Dendritic cells are immune cells that can signal to the immune system to fight infection. The vaccines used in this trial are made of dendritic cells that have been sensitized to HER2 and HER3 receptors, which can be found on some tumor cells. Administering these vaccines may induce an immune response against tumor cells.